Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-Pentatrichomonas hominis activity of newly synthesized benzimidazole derivatives — in vitro studies

Anti-Pentatrichomonas hominis activity of newly synthesized benzimidazole derivatives — in vitro... Pentatrichomonas hominis, a parasitic protozoan often detected in human diarrheic stools, is the cause of severe morbidity in newborns and children, particularly in tropical zones. The flagellate is resistant to many disinfectants and anti-protozoan drugs. Therefore in this study we have synthesized three novel 4,5,6,7-tetrabromobenzimidazole (TBBI) derivatives carrying a polyfluoroalkyl substituent in position 2 of the benzimidazole scaffold, namely 2-trifluoromethyl-TBBI (CF3-TBBI), 2-nonafluorobutyl-TBBI (C4F9-TBBI), and 2-nonadecafluorononyl-TBBI (C9F19-TBBI), that next we tested for their in vitro activity against P. hominis.Widely applied anti-protozoal drug, metronidazole as a reference was used. All the investigated agents were added to 24 h P. hominis cultures; each of them was administered at three different concentrations. Number of the moving trichomonads was determined and compared with the control cultures. Different anti-trichomonal activity occurred depending on a kind of compound and its concentration. C4F9-TBBI was the most effective TBBI derivative tested: the agent, at the highest concentration 24.2 μg/ml, after 72 h reduced the number of viable trichomonads to 44.3%; C9F19-TBBI, at the concentration 24 μg/ml reduced the number of the flagellates to 58.5%. Paradoxically, metronidazole after the same time given at the highest concentration increased trophozoite counts by 464.6% in comparison with the control cultures (100%). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Parasitologica Springer Journals

Anti-Pentatrichomonas hominis activity of newly synthesized benzimidazole derivatives — in vitro studies

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/anti-pentatrichomonas-hominis-activity-of-newly-synthesized-0hl0k0NhR6

References (94)

Publisher
Springer Journals
Copyright
Copyright © 2009 by © Versita Warsaw and Springer-Verlag Berlin Heidelberg
Subject
Life Sciences; Microbiology ; Medical Microbiology ; Ecology; Zoology ; Life Sciences, general
ISSN
1230-2821
eISSN
1896-1851
DOI
10.2478/s11686-009-0024-4
Publisher site
See Article on Publisher Site

Abstract

Pentatrichomonas hominis, a parasitic protozoan often detected in human diarrheic stools, is the cause of severe morbidity in newborns and children, particularly in tropical zones. The flagellate is resistant to many disinfectants and anti-protozoan drugs. Therefore in this study we have synthesized three novel 4,5,6,7-tetrabromobenzimidazole (TBBI) derivatives carrying a polyfluoroalkyl substituent in position 2 of the benzimidazole scaffold, namely 2-trifluoromethyl-TBBI (CF3-TBBI), 2-nonafluorobutyl-TBBI (C4F9-TBBI), and 2-nonadecafluorononyl-TBBI (C9F19-TBBI), that next we tested for their in vitro activity against P. hominis.Widely applied anti-protozoal drug, metronidazole as a reference was used. All the investigated agents were added to 24 h P. hominis cultures; each of them was administered at three different concentrations. Number of the moving trichomonads was determined and compared with the control cultures. Different anti-trichomonal activity occurred depending on a kind of compound and its concentration. C4F9-TBBI was the most effective TBBI derivative tested: the agent, at the highest concentration 24.2 μg/ml, after 72 h reduced the number of viable trichomonads to 44.3%; C9F19-TBBI, at the concentration 24 μg/ml reduced the number of the flagellates to 58.5%. Paradoxically, metronidazole after the same time given at the highest concentration increased trophozoite counts by 464.6% in comparison with the control cultures (100%).

Journal

Acta Parasitologica – Springer Journals

Published: Apr 25, 2009

There are no references for this article.